Shenzhen Neptunus Bioengineering (000078.SZ) issued a forecasted preloss, predicting a net loss of 950 million to 1.2 billion yuan for the year 2024.

Shenzhen Neptunus Bioengineering (000078.SZ) released its annual performance forecast for 2024, expecting a net loss of 950 million to 1.2 billion yuan attributable to the shareholders of the listed company for the full year. In recent years, as the national healthcare system reform has continued to deepen, pharmaceutical distribution enterprises are facing increasing pressure in their operational management. During the reporting period, with the continuous advancement of policies such as centralized volume-based procurement and price reductions in medical insurance negotiations, the company's profit margins were further affected. The company's main hospital clients are suffering from continued financial strain, resulting in a prolonged accounts receivable turnover period, affecting the company's operational cash flow efficiency, leading to a reduction in the company's business scale and profits.